THE FDA DESIGNATED BREAKTHROUGH DEVICE

Detect and monitor brain diseases through typing cadence

How do we perform our magic?

Simple: We measure typing inconsistency

NeuraMetrix Typing Cadence (TC) passive digital brain-health biomarker:
  • Detects and monitors neurological diseases and psychiatric disorders by continuously measuring typing cadence.
  • Is a patented digital biomarker.
  • Designated “Breakthrough Device” by the US FDA for Parkinson’s Disease.
  • Is not FDA-cleared or CE-marked.
  • Can be sold under Internal Review Board (IRB) approval for research globally.
typing-on-keyboard-topdown
typing-on-keyboard-sideview

How do we change the world?

Our Goal is to dramatically improve care for patients with various neurological diseases and psychiatric disorders by providing researchers, physicians, and patients with passive, continuous, exceptionally precise, and accurate measurements of brain health.​​​ 

Or, as a leading neuroscientist puts it

"Imprecise, inaccessible, and outdated assessments of cognition dominate the mental health world". - Professor Adam Gazzaley, M.D., University of California San Francisco

From the experts

//

"We have been looking for this for 30 years."


- Dr. Robert W. Mahley, M.D. Ph.D.
Senior Investigator, President Emeritus and Founder, Gladstone Institutes, Senior Investigator, Gladstone Institute of Neurological Disease, Professor of Pathology and Medicine, University of California San Francisco, Chairman, NeuraMetrix’ Scientific Advisory Board
​​​​​​​​​​​​​​
//

"We train our Huntington’s patients intensively. I am amazed that the effects are so clearly shown in the inconsistency scores."


- Dr. Christina Lang, M.D. – Department of Neurology, Universität Ulm, Germany
​​​​​​​
//

"This will revolutionize how we treat these poor patients."


- CTO of major hospital system in Scandinavia
​​​​​​​
//

"NeuraMetrix technology has potential to provide first-in-class early detection of affective disorders potentially fast-tracking diagnosis and reducing burden of illness."


- Dr. Martin Schalling, M.D., Professor of Medical Genetics Karolinska Institutet,  Chair Swedish Mental Health Fund
​​​​​​​
//

"Digital is the new blood: Enabling the Present and the Future."


- Dr. Rhoda Au, Ph.D.
Professor, Boston University, co-PI, Framingham Heart Study Brain Aging Project & Director of Neuropsychology

Source
​​​​​​​

Some of our Research Partners

lund-transparentt
uppsala-transparent-logo
phillips-universitat

Upcoming Events

No currently planned upcoming events

Sign up for the NeuraMetrix newsletter